Promiximab-DUBA was also highly efficacious in vivo, with tumor regression generally achieved with three times injection at a dose of 5 mg/kg and 10 mg/kg in the NCI-H526 xenograft model. The gene discussed is OTUD5; the disease is neoplasm.